June 14, 2024 07:00 AM EDTUpdated 09:00 AM

Bill Haney gives up CEO post at Skyhawk, becomes chairman; Bayer parts ways with head of biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Bill Haney has helped Skyhawk Therapeutics stand out in the wave of biotechs looking to drug RNA, taking over from fellow co-founder Kathleen McCarthy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bill Haney gives up CEO post at Skyhawk, becomes chairman; Bayer parts ways with head of biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Bill Haney gives up CEO post at Sky­hawk, be­comes chair­man; Bay­er parts ways with head of biotech

Copy Chief

Editor

Sign up to read this article for free.

Bill Haney gives up CEO post at Skyhawk, becomes chairman; Bayer parts ways with head of biotech